PARK, SANG GEUN,SHIN, HYE GYEONG,BAE, JEONG WOO,CHOI, HYUN JU
申请号：
CA2984235
公开号：
CA2984235A1
申请日:
2016.04.27
申请国别(地区):
CA
年份:
2016
代理人:
摘要：
The present invention relates to a kind of sustained release pharmaceutical compositions containing rivastigmine, more specifically, it is related to a kind of sustained release pharmaceutical composition containing rivastigmine, it be a kind of sustained release preparation include the pH dependences delayed release stage, it wherein can be minimized the pharmaceutical composition in the administration of stomach initial stage by the pharmaceutical composition of control release, it can reduce while maximum haemoconcentration (maximum concentration) compares existing product and reach effective blood drug concentration, to reduce side effect, hereafter, effective blood concentration is maintained to pass through sustained release major ingredient. Therefore, pharmaceutical composition of the invention shows identical effect, only can improve the patient for the treatment of effeciency by dosage once a day with existing twice a day take medicine, and the patient of administration is deeply convinced by improving.
